PCDHA10

Across TCGA pan-cancer cohorts, PCDHA10 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated PCDHA10 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher PCDHA10 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PCDHA10 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

KIRC, UCS, and UCEC are the cancer types where PCDHA10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	All	0.180	0.796	.001	24	view →
UCS	OS	Median	All	0.135	0.687	.009	24	view →
UCEC	DFS	Median	All	0.777	0.623	.021	24	view →
PAAD	OS	Median	All	0.037	0.641	<.001	12	view →
OV	DFS	Median	All	0.339	0.543	.045	12	view →
ESCA	OS	Median	II,III,IV	0.109	0.931	.003	12	view →
HNSC	OS	Median	All	0.174	0.710	.015	12	view →
LIHC	OS	Median	III,IV	0.094	0.615	<.001	12	view →
LUAD	DFS	Median	All	0.736	0.333	.017	10	view →
LGG	DFS	Median	All	0.080	0.826	<.001	6	view →
DLBC	DFS	Median	II,III,IV	0.022	0.800	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

PCDHA10–KIRC (DFS)

Open the KIRC breakdown →